Please assess the completion status of the following clinical trial:

Trial Title: Study to Examine Safety, Tolerability, and Effect on Body Weight of Metreleptin Administered in Conjunction With Pramlintide in Obese and Overweight Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 8.0

Eligibility Criteria:
Inclusion Criteria:~* 18 to 65 years old.~* Is obese (Body Mass Index \[BMI\]\>=30kg/m\^2 and \<=35kg/m\^2); or overweight (BMI\>=27kg/m\^2 and \<30kg/m\^2.~* Has stable body weight, i.e., not varying by \>3% within 3 months prior to study.~* Has not been treated over the past 3 months or is currently treated with any of the following medications: Oral contraceptives (female subjects); Hormone replacement therapy (female subjects); Metformin for the treatment of polycystic ovary syndrome (female subjects); Antihypertensive agents; Lipid-lowering agents; Thyroid replacement therapy; selective serotonin reuptake inhibitors (SSRIs).~* Is comfortable with having repeated telephone contacts with a lifestyle counselor during the study.~* Is a nonsmoker (has not smoked for at least 6 months prior to the study).~Exclusion Criteria:~* Has a medical history (e.g., morbid childhood obesity) and/or physical characteristics suggestive of genetic obesity or syndromatic obesity (e.g., Prader-Willi syndrome, Bardet-Biedl syndrome).~* Is currently enrolled or plans to enroll in a diet, weight loss, or exercise program with the specific intent of losing weight (subjects who have been following an exercise regimen resulting in stable weight maintenance for at least 2 months prior to enrollment are eligible for study inclusion)~* Has been treated over the past 2 months, is currently treated, or is expected to require or undergo treatment with \*antiobesity agents (prescription or over-the-counter), \*antipsychotic agents, \*antiepileptic agents, \*antidepressant agents, \*drugs that directly affect gastrointestinal motility, \*antidiabetic medications.~* Has previously received treatment with metreleptin or pramlintide in a clinical study or has received prior treatment with pramlintide (SYMLIN®).~* Has received any investigational drug within 30 days or within a period corresponding to 5 half-lives of that drug, whichever is greater, prior to this study starting.~* Has had a major surgery or a blood transfusion, or has donated blood over the past 2 months or is planning to donate blood during the study.~* Has had liposuction, abdominoplasty, or similar procedure over the past year or is planning to have such a procedure during the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Placebo-P + Placebo-M (Type: PLACEBO_COMPARATOR): Placebo matched to pramlintide BID plus placebo matched to metreleptin BID
- Pramlintide 360 mcg + Placebo-M (Type: EXPERIMENTAL): 360 mcg pramlintide given twice per day (BID) plus Placebo matched to Metreleptin given BID
- Placebo-P + Metreleptin 5.0 mg (Type: EXPERIMENTAL): Placebo matched to pramlintide BID plus metreleptin 5.0 mg BID
- Pramlintide 180 mcg + Metreleptin 2.5 mg (Type: EXPERIMENTAL): Pramlintide 180 mcg BID plus Metreleptin 2.5 mg BID
- Pramlintide 180 mcg + Metreleptin 5.0 mg (Type: EXPERIMENTAL): Pramlintide 180 mcg BID plus Metreleptin 5.0 mg BID
- Pramlintide 360 mcg + Metreleptin 1.25 mg (Type: EXPERIMENTAL): Pramlintide 360 mcg BID plus Metreleptin 1.25 mg BID
- Pramlintide 360 mcg + Metreleptin 2.5 mg (Type: EXPERIMENTAL): Pramlintide 360 mcg BID plus Metreleptin 2.5 mg BID
- Pramlintide 360 mcg + Metreleptin 5.0 mg (Type: EXPERIMENTAL): Pramlintide 360 mcg BID plus Metreleptin 5.0 mg BID

Based on this trial design, predict the completion outcome and termination type (if applicable).